Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Q32 Bio Inc
QTTBCurrent price
35.63 USD
-3.86 USD (-9.77%)
Last closed
39.73 USD
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
556 559 808 USD
Yield for 12 month
+124.94 %
1Y
3Y
5Y
10Y
15Y
QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. Address: 830 Winter Street, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
77.8 USDP/E ratio
–Dividend Yield
–Current Year
+1 156 000 USD
Last Year
+6 651 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+578 000 USD
Last Year
+4 052 000 USD
Current Quarter
-121 000 USD
Last Quarter
-123 000 USD
Key Figures QTTB
1 year
3 years
5 years
10 years
EBITDA
-65 877 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
–
PEG Ratio
–
Return On Equity TTM
–
Wall Street Target Price
77.8 USD
Revenue TTM
-12 803 000 USD
Book Value
2.79 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-4.5 USD
Diluted Eps TTM
-4.5 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics QTTB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History QTTB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:18
Payout Ratio
–
Last Split Date
26.03.2024
Dividend Date
–
Stock Valuation QTTB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
–
Price Book MRQ
16.6083
Financials QTTB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators QTTB
For 52 weeks
8.24 USD
53.79 USD
50 Day MA
35.87 USD
Shares Short Prior Month
608 184
200 Day MA
22.13 USD
Short Ratio
3.65
Shares Short
678 638
Short Percent
–
BeatStart